The Cardiometabolic Continuum: Why Inflammation Is Becoming the New Vital Sign

The reframing is significant. A 2025 perspective in the Journal of Clinical Medicine argues that type 2 diabetes and cardiovascular disease are not two separate epidemics that happen to overlap, but co-evolving manifestations of a shared cardiometabolic continuum — one driven by chronic inflammation, dysfunctional fat tissue, and the chatter between organs that we used to treat in isolation. In plain English: your liver, your fat cells, your pancreas, and your arteries are in a group chat, and the tone of that chat is set largely by inflammation.

This is not a fringe idea anymore. The same perspective notes that even with aggressive glycemic, lipid, and blood pressure control, residual cardiovascular risk remains stubbornly high, which is a polite way of saying that hitting our usual numbers isn't enough. Something else is doing damage in the background. Increasingly, the suspect is low-grade, smoldering inflammation that no one ordered a test for.

Here's where it gets interesting for the optimizer set. A 2026 clinical study in Metabolic Syndrome and Related Disorders looked at three blood biomarkers — high-sensitivity C-reactive protein (hsCRP), Fetuin-A, and YKL-40 — in people with metabolic syndrome versus healthy controls. All three were significantly elevated in the metabolic syndrome group. More striking: when researchers tracked patients over three months of lifestyle changes alone, shifts in severity scores moved in lockstep with shifts in the biomarkers, with correlations of 0.84 for hsCRP, 0.92 for Fetuin-A, and 0.91 for YKL-40.

Translation: when these women got serious about food and movement, the inflammatory signature in their blood moved with them — and the more the severity dropped, the more the biomarkers dropped. That's the kind of feedback loop that anyone who has ever screamed at a bathroom scale would actually find useful.

A caveat before anyone runs off to order their own panel: this was a small study — 47 patients and 23 controls — and it doesn't prove these biomarkers should replace anything in your current workup. But it does suggest they're tracking something real, and something the standard panel doesn't see.

If you've heard the acronym MASLD lately and assumed it was someone else's problem, this is the part to read twice. Metabolic dysfunction–associated steatotic liver disease is the new name for what most of us still call fatty liver, and a 2026 systematic review in Current Obesity Reports describes it as the hepatic manifestation of ectopic fat accumulation and adipose tissue dysfunction — i.e., the liver expression of a whole-body problem.

What the reviewers found is unsettling in a fascinating way. Excess visceral fat appears to drive adipose tissue hypoxia, macrophage infiltration, and chronic low-grade systemic inflammation that doesn't stay polite about staying in the abdomen. They describe a proposed liver–lung axis, where the same inflammatory traffic that scars the liver seems to show up in the airways. Across 22 studies, MASLD was common in people with COPD and obstructive sleep apnea and was associated with worse respiratory phenotypes, more exacerbations, and higher respiratory mortality in several cohorts. Liver fibrosis, more than steatosis itself, seemed to track most closely with impaired lung function.

This is a systematic review of mostly observational data, so cause-and-effect is not nailed down. But the pattern is consistent enough — and the mechanism plausible enough — that thinking of these as separate diseases is starting to look quaint.

None of this is permission to bypass your clinician with a shopping cart of obscure lab tests. Some of these biomarkers — Fetuin-A and YKL-40 in particular — are still being evaluated for clinical utility, not yet a standard part of care. hsCRP, by contrast, is widely available, inexpensive, and a reasonable conversation-starter at your next appointment, especially if you have any combination of central weight gain, rising blood pressure, borderline glucose, or a family history of early heart disease.

The bigger shift is conceptual. If diabetes, fatty liver, and heart disease are points on one continuum, then the most useful question to bring to a clinician isn't "Am I diabetic yet?" It's "What's my inflammatory load, and what is it doing to me?" That reframing matters most in midlife, when perimenopausal hormonal shifts are already reshuffling fat distribution, sleep, and lipid handling — exactly the levers this continuum runs on.

The honest summary: we are not at the point where a single blood draw tells you your cardiometabolic future. We are at the point where the field is openly admitting the old dashboard is incomplete, and the new gauges are being prototyped in real time. That's worth knowing before your next physical — because the questions you ask in that 15-minute appointment are the ones most likely to change what gets measured.